{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:13:14Z","timestamp":1786975994887,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd005449","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T00:00:00Z","timestamp":1352851200000}}],"reference-count":82,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005449.pub2","type":"journal-article","created":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T19:30:12Z","timestamp":1352403012000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus"],"prefix":"10.1002","volume":"2012","author":[{"given":"Nyoli","family":"Valentine","sequence":"first","affiliation":[{"name":"Bond University; Department of General Practice; Gold Coast Queensland Australia 4229"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris A","family":"Van de Laar","sequence":"additional","affiliation":[{"name":"Radboud University Nijmegen Medical Center; Department of Primary and Community Care, 117 ELG; PO Box 9101 Nijmegen Netherlands 6500 HB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke L","family":"van Driel","sequence":"additional","affiliation":[{"name":"The University of Queensland; Discipline of General Practice, School of Medicine; Brisbane Queensland Australia 4006"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,11,14]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD005449.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1052-3057(98)80127-4","article-title":"African American Antiplatelet Stroke Prevention Study: clinical trial design","volume":"7","author":"Gorelick","year":"1998","journal-title":"Journal of Stroke and Cerebrovascular Diseases"},{"issue":"22","key":"10.1002\/14651858.CD005449.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.289.22.2947","article-title":"Aspirin and ticlopidine for prevention of recurrent stroke in black patients","volume":"289","author":"Gorelick","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","article-title":"Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus","volume":"90","author":"Bhatt","year":"2002","journal-title":"The American Journal of Cardiology"},{"issue":"9038","key":"10.1002\/14651858.CD005449.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"The Lancet"},{"issue":"3","key":"10.1002\/14651858.CD005449.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1358836X9800300314","article-title":"Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events","volume":"3","author":"Creager","year":"1998","journal-title":"Vascular Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005449.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00002018-199921040-00007","article-title":"Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events","volume":"21","author":"Harker","year":"1999","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1001\/archinte.164.19.2106","article-title":"Comparative benefits of clopidogrel and aspirin in high-risk patient populations","volume":"164","author":"Hirsh","year":"2004","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/01.STR.19.10.1203","article-title":"The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organisation, and baseline results","volume":"19","author":"Gent","year":"1988","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","article-title":"The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke","volume":"8649","author":"Gent","year":"1989","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0010|cit10","first-page":"283","article-title":"Canadian American ticlopidine study (cats) in thromboembolic stroke","volume":"15","author":"Gent","year":"1984","journal-title":"Agents and Actions. Supplements"},{"issue":"4","key":"10.1002\/14651858.CD005449.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3949\/ccjm.75.4.289","article-title":"Interpreting the CHARISMA study. What is the role of dual antiplatelet therapy with clopidogrel and aspirin?","volume":"75","author":"Bakhru","year":"2008","journal-title":"Cleveland Clinic Journal of Medicine"},{"issue":"19","key":"10.1002\/14651858.CD005449.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"issue":"16","key":"10.1002\/14651858.CD005449.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD005449.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ahj.2004.03.028","article-title":"Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial","volume":"148","author":"Bhatt","year":"2004","journal-title":"American Heart Journal"},{"issue":"6-7","key":"10.1002\/14651858.CD005449.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.acvd.2009.03.012","article-title":"Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial","volume":"102","author":"Collet","year":"2009","journal-title":"Archives of Cardiovascular Diseases"},{"issue":"10","key":"10.1002\/14651858.CD005449.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.amjcard.2009.01.342","article-title":"Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischaemic stabilization, management, and avoidance [CHARISMA] trial)","volume":"103","author":"Dasgupta","year":"2009","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD005449.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/eurheartj\/ehn565","article-title":"The peripheral arterial disease subgroup in the CHARISMA trial: does it tell us anything new?","volume":"30","author":"Gresele","year":"2009","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD005449.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1747-4949.2010.00535.x","article-title":"Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial","volume":"6","author":"Hankey","year":"2011","journal-title":"International Journal of Stroke"},{"issue":"18","key":"10.1002\/14651858.CD005449.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/eurheartj\/ehm274","article-title":"An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial","volume":"28","author":"Wang","year":"2007","journal-title":"European Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD005449.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"issue":"19","key":"10.1002\/14651858.CD005449.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1001\/archinte.164.19.2106","article-title":"Comparative benefits of clopidogrel and aspirin in high-risk patient populations: Lessons from the CAPRIE and CURE studies","volume":"164","author":"Hirsh","year":"2004","journal-title":"Archives of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD005449.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD005449.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators","year":"2001","journal-title":"The New England Journal of Medicine"},{"issue":"15","key":"10.1002\/14651858.CD005449.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluding stents","volume":"362","author":"Park","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005449.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1161\/STROKEAHA.109.564906","article-title":"Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis","volume":"41","author":"Bath","year":"2010","journal-title":"Stroke"},{"issue":"9","key":"10.1002\/14651858.CD005449.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1586\/14737175.7.9.1085","article-title":"The PRoFESS trial: future impact on secondary stroke prevention","volume":"7","author":"Diener","year":"2007","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"5-6","key":"10.1002\/14651858.CD005449.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000100105","article-title":"Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS)","volume":"23","author":"Diener","year":"2007","journal-title":"Cerebrovascular Diseases"},{"issue":"12","key":"10.1002\/14651858.CD005449.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD005449.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1161\/01.STR.24.10.1452","article-title":"Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The ticlopidine aspirin stroke study","volume":"24","author":"Bellavance","year":"1993","journal-title":"Stroke"},{"issue":"1","key":"10.1002\/14651858.CD005449.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1212\/WNL.42.1.111","article-title":"Prevention of stroke with ticlopidine: Who benefits most?","volume":"42","author":"Grutta","year":"1992","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD005449.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1161\/01.STR.23.12.1723","article-title":"Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the ticlopidine aspirin stroke study","volume":"23","author":"Harbison","year":"1992","journal-title":"Stroke"},{"issue":"8","key":"10.1002\/14651858.CD005449.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","article-title":"A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients","volume":"321","author":"Hass","year":"1989","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1052-3057(10)80131-4","article-title":"Ticlopidine aspirin stroke study: outcome by vascular distribution of the qualifying event","volume":"3","author":"Pryse-Phillips","year":"1993","journal-title":"Journal of Stroke and Cerebrovascular Diseases"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1052-3057(10)80157-0","article-title":"Ticlopidine versus aspirin for stroke prevention: on-treatment results from the ticlopidine aspirin stroke study","volume":"3","author":"Ticlopidine Aspirin Stroke Study Group","year":"1993","journal-title":"Journal of Stroke and Cerebrovascular Diseases"},{"issue":"1","key":"10.1002\/14651858.CD005449.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1212\/WNL.43.1_Part_1.27","article-title":"The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the ticlopidine aspirin stroke study","volume":"43","author":"Weisberg","year":"1993","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD005449.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.CIR.82.1.17","article-title":"Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial","volume":"82","author":"Balsano","year":"1990","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD005449.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ahj.2010.05.017","article-title":"Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event","volume":"160","author":"Wang","year":"2010","journal-title":"American Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD005449.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"issue":"9497","key":"10.1002\/14651858.CD005449.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"The Lancet"},{"issue":"19","key":"10.1002\/14651858.CD005449.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD005449.pub2-BIB0041|cit41","first-page":"329","article-title":"The effects of ticlopidine in acute myocardial infarction as an adjunctive treatment to aspirin in an intermediate term setting","volume":"32","author":"Cun","year":"2002","journal-title":"Turkish Journal of Medical Sciences"},{"issue":"24","key":"10.1002\/14651858.CD005449.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD005449.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1253\/jcj.61.38","article-title":"Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group","volume":"61","author":"Ishikawa","year":"1997","journal-title":"Japanese Circulation Journal"},{"issue":"25","key":"10.1002\/14651858.CD005449.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.104.502815","article-title":"Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial","volume":"111","author":"Wiviott","year":"2005","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD005449.pub2-BIB0045|cit45","first-page":"476","article-title":"A randomized trial comparing ticlopidine with aspirin for the prevention of ischaemic cerebral stroke","volume":"20","author":"Li","year":"1999","journal-title":"Acta Pharmacologica Sinica"},{"issue":"6","key":"10.1002\/14651858.CD005449.pub2-BIB0046|cit46","first-page":"431","article-title":"Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting: follow-up results of a randomized study","volume":"13","author":"Machraoui","year":"June 2001","journal-title":"Journal of Invasive Cardiology"},{"issue":"9431","key":"10.1002\/14651858.CD005449.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"The Lancet"},{"issue":"6","key":"10.1002\/14651858.CD005449.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0735-1097(02)02974-1","article-title":"A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents","volume":"41","author":"Mueller","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD005449.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD005449.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0735-1097(01)01164-0","article-title":"Ticlopidine versus aspirin after myocardial infarction (STAMI) trial","volume":"37","author":"Scrutinio","year":"2001","journal-title":"Journal of American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD005449.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2796.1990.tb00164.x","article-title":"Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study","volume":"227","author":"Janzon","year":"1990","journal-title":"Journal of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD005449.pub2-BIB0052|cit52","first-page":"33","article-title":"A randomized trial comparing ticlopidine hydrochloride with ibuprofen for the prevention of stroke in high-risk patients (TISS Study). Ticlopidine Indobufen Stroke Study","volume":"12","author":"Bergamasco","year":"1997","journal-title":"Functional Neurology"},{"issue":"1","key":"10.1002\/14651858.CD005449.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2169\/internalmedicine1962.26.117","article-title":"The effect of ticlopidine on TIA compared with aspirin - a double-blind, twelve-month and open 24 month follow up study","volume":"26","author":"Tohgi","year":"1987","journal-title":"Japanese Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD005449.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2169\/internalmedicine.42.793","article-title":"Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke (the Tokai Panaldine Aspirin Long-term Study (TOPALS))","volume":"42","author":"Ito","year":"2003","journal-title":"Internal Medicine"},{"issue":"20","key":"10.1002\/14651858.CD005449.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wivott","year":"2007","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD005449.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1747-4949.2010.00573.x","article-title":"The secondary prevention of small subcortical strokes (SPS3) study","volume":"6","author":"Benavente","year":"April 2011","journal-title":"International Journal of Stroke"},{"issue":"7","key":"10.1002\/14651858.CD005449.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2337\/diacare.20.7.1183","article-title":"Report of the Expert Committee on the diagnosis and classification of diabetes mellitus","volume":"20","author":"American Diabetes Association","year":"1997","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005449.pub2-BIB0058|cit58","first-page":"S1","article-title":"The Expert Committee on the diagnosis and classification of diabetes mellitus","volume":"22","author":"American Diabetes Association","year":"1999","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005449.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"s11","DOI":"10.2337\/dc11-S011","article-title":"Standards of medical care in diabetes-2011","volume":"34","author":"American Diabetes Association","year":"2011","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD005449.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.beem.2008.12.001","article-title":"Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus","volume":"23","author":"Angiolillo","year":"2009 Jun","journal-title":"Best Practice & Research Clinical Endocrinology & Metabolism"},{"issue":"7329","key":"10.1002\/14651858.CD005449.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists' Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD005449.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","article-title":"Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus","volume":"90","author":"Bhatt","year":"2002","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD005449.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1161\/01.ATV.0000122852.22604.78","article-title":"Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited","volume":"24","author":"Ceriello","year":"2004","journal-title":"Arteriosclerosis, thrombosis, and vascular biology 1: Arteriosclerosis, thrombosis, and vascular biology"},{"issue":"12","key":"10.1002\/14651858.CD005449.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.2337\/diacare.26.12.3349","article-title":"Aspirin for primary prevention of cardiovascular events in diabetes","volume":"26","author":"Colwell","year":"2003","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD005449.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1345\/aph.1P319","article-title":"Thienopyridines in acute coronary syndrome","volume":"45","author":"Goodwin","year":"2011","journal-title":"The Annals of Pharmacotherapy"},{"issue":"7","key":"10.1002\/14651858.CD005449.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.2337\/diacare.21.7.1138","article-title":"Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993","volume":"21","author":"Gu","year":"1998","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD005449.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD005449.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0070|cit70","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD005449.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1046\/j.1365-2044.2003.02960.x","article-title":"The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and developments","volume":"58","author":"Kam","year":"2003","journal-title":"Anaesthesia"},{"issue":"2","key":"10.1002\/14651858.CD005449.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.0954-6820.1986.tb03298.x","article-title":"Evaluation of platelet reactivity in diabetes mellitus","volume":"219","author":"Kutti","year":"1986","journal-title":"Acta Medica Scandinavica"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","article-title":"The case of the misleading funnel plot","volume":"333","author":"Lau","year":"2006","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD005449.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"1999","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0075|cit75","unstructured":"National Insitute for Health and Clinical Excellence Unstable angina and NSTEMI. The early management of unstable angina and non-ST-segment-elevation myocardial infarction. Clinical guideline 94 http:\/\/guidance.nice.org.uk\/CG94\/NICEGuidance\/pdf\/English (accessed March 2010)"},{"issue":"1","key":"10.1002\/14651858.CD005449.pub2-BIB0076|cit76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005158.pub3","article-title":"Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease","author":"Squizzato","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/9780470693926.ch11","article-title":"Investigating and dealing with publication and other biases","volume-title":"Systematic Reviews in Health Care; Meta-analysis in Context","author":"Sterne","year":"2001"},{"issue":"4","key":"10.1002\/14651858.CD005449.pub2-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001246.pub2","article-title":"Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients","author":"Sudlow","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0079|cit79","unstructured":"WHO Expert Committee on Diabetes Mellitus Second report World Health Organisation: Technical Report Series 646; 1980"},{"key":"10.1002\/14651858.CD005449.pub2-BIB0080|cit80","unstructured":"World Health Organisation Diabetes Mellitus: Report of a WHO Study Group World Health Organisation: Technical Report Series No. 727; 1985"},{"issue":"7","key":"10.1002\/14651858.CD005449.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetic Medicine"},{"issue":"5","key":"10.1002\/14651858.CD005449.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005449.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T10:03:42Z","timestamp":1722247422000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005449.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Metabolic and Endocrine Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,11,14]]},"references-count":82,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005449.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,14]]}}}